Usefulness of GLP-1 receptor agonists in patients with type 2 diabetes who are receiving antipsychotic therapy and have obesity or fatty liver

Usefulness of GLP-1 receptor agonists in patients with type 2 diabetes who are receiving antipsychotic therapy and have obesity or fatty liver - Usefulness of GLP-1 receptor agonists in patients receiving antipsychotic therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060936

Enrollment

Registered

2026-04-01

Start date

2026-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with type 2 diabetes who are receiving antipsychotic therapy and have obesity or fatty liver

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with type 2 diabetes who are currently receiving antipsychotic medication and have not yet been treated with a GLP-1 receptor agonist (2) BMI greater than 27 or diagnosis of fatty liver by imaging (ultrasound or CT) Patients who meet both criteria (1) and (2) will begin treatment with a GLP-1 receptor agonist.

Exclusion criteria

Exclusion criteria: Inability to comply with GLP-1 receptor agonist therapy Any other condition judged inappropriate by the attending physician

Design outcomes

Primary

Measure	Time frame
changes of BMI, serum ALT levels and HbA1c	—

Secondary

Measure	Time frame
body fat percentage and muscle mass	—

Countries

Japan

Contacts

Public ContactYoshimichi Haruna

Osaka Prefectural Hospital Organization Osaka Psychiatric Medical Center Department of Medical Affairs

apple-123-grape@ab.auone-net.jp072-847-3261

Outcome results